ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 175

Associations Between Circulating Cytokines and Incident Inflammatory Arthritis in an Anti-citrullinated Protein Antibody Positive Population

Kristen Polinski1, Elizabeth Bemis 2, M. Kristen Demoruelle 3, Marie Feser 4, LauraKay Moss 5, Jennifer Seifert 6, Michael Clare-Salzler 7, William Robinson 8, V. Michael Holers 6, Kevin Deane 4 and Jill Norris 9, 1University of Colorado Denver, Aurora, CO, 2University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, 4University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 5University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, 6University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 7Department of Pathology, University of Florida, Gainesville, FL, 8Stanford University, Stanford, CA, 9Colorado School of Public Health, Aurora

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cytokines and inflammatory arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Epidemiology & Public Health Poster I: RA

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Elevated circulating cytokines are present years before the onset of rheumatoid arthritis (RA). We conducted a prospective cohort study in an at-risk population of anti-cyclic citrullinated peptide (CCP) antibody positive individuals to determine if serum cytokines predict the development of incident inflammatory arthritis (IA).

Methods: Participants were recruited into the cohort if they were a first degree relative (FDR) of a RA proband or were screened at health fairs. For the present analysis we included n=137 CCP positive participants contributing 508 person-years of follow-up for the appearance of IA (CCP3.1 Inova). During follow-up 29 participants developed IA (defined as having at least 1 joint consistent with RA-like synovitis based on exam), and of those participants 22 were classified as RA by 2010 ACR/EULAR criteria. The concentrations of interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-α were quantified from stored serum at baseline and each follow-up visit for a total of n=525 visits. Each of these cytokines and chemokines have previously been implicated in RA pathogenesis. We conducted a survival (i.e. time-to-event) analysis using Cox proportional hazard models with log transformed cytokine concentrations as time-varying predictors and obtained hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: Baseline characteristics by incident IA status are presented in Table 1. Participants who went on to develop IA were significantly more likely to test positive for the shared epitope compared to participants who did not develop IA (p-value = 0.02). We found a significant positive association of serum TNF-α with incident IA risk, adjusting for cohort (FDR or screened), shared epitope status and age at baseline (adjusted HR: 1.97; 95%CI: 1.08, 3.58). The association of IL-6 and IA risk trended in the same direction but did not reach statistical significance (adjusted HR: 1.27; 95%CI: 0.93, 1.74).

Conclusion: In a cohort of DMARD untreated CCP positive individuals, we demonstrated that circulating levels of TNF-α, a potential indicator of systemic inflammation, was positively associated with incident IA. This finding further supports the dysregulation or failure in the ability to resolve inflammation in preclinical RA patients.


Table 1


Table 2


Disclosure: K. Polinski, Pfizer, 2; E. Bemis, None; M. Demoruelle, Pfizer, 2; M. Feser, None; L. Moss, None; J. Seifert, Janssen, 2; M. Clare-Salzler, None; W. Robinson, None; V. Holers, AdMIRx, 1, 2, 4, 5, 6, Alexion, 7, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 5, Janssen R&D, 2, 5, Pfizer, 2; K. Deane, Bristol-Myers Squibb, 5, Inova, 9, Janssen, 2, 5, Janssen R&D, 2, Microdrop, 5, Pfizer, 2; J. Norris, BMS, 5, Celgene, 5, Janssen R&D, 2, Pfizer, 2.

To cite this abstract in AMA style:

Polinski K, Bemis E, Demoruelle M, Feser M, Moss L, Seifert J, Clare-Salzler M, Robinson W, Holers V, Deane K, Norris J. Associations Between Circulating Cytokines and Incident Inflammatory Arthritis in an Anti-citrullinated Protein Antibody Positive Population [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/associations-between-circulating-cytokines-and-incident-inflammatory-arthritis-in-an-anti-citrullinated-protein-antibody-positive-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-circulating-cytokines-and-incident-inflammatory-arthritis-in-an-anti-citrullinated-protein-antibody-positive-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology